From this series, LS-1-2 emerged as a preclinical drug candidate, demonstrating potent anti-proliferative and anti-metastatic efficacy in both in vitro and in vivo models of KRAS-mutant colorectal cancer. The gene discussed is KRAS; the disease is colorectal cancer.